Introduction
Transporters are membrane proteins with multiple membrane-spanning domains, which facilitate the permeation of low-molecular-weight compounds and ions across biological membranes. Unlike passive diffusion, membrane permeation mediated by transporters is characterized by saturability. Increasing the substrate concentration causes a proportional increase in the transport velocity, but the transport velocity ultimately reaches a steady value. In vivo and in vitro studies have demonstrated that saturable mechanisms are involved in the tissue uptake and subsequent efflux processes of certain types of drugs, which account for the specific tissue distributions and elimination pathways of drugs from the body. The accumulation of these data has established the importance of transporters in drug disposition [1] [2] [3] and ultimately in the drug response. 2) Transporters are expressed in the liver and kidney, two major clearance organs of the body, and are involved in the elimination of drugs from the systemic circulation. Hense, they determine the exposure of the pharmacological target to the drug. Transporters are also involved in the uptake and/or efflux in the peripheral organs and thus determine the exposure of the pharmacological target to the drug. 2) Examples of the latter include the blood-tissue barriers, such as the blood-brain barrier.
During the last decade, many types of transporters have been identified in animals and humans, encoded by more than 400 genes, and among those are orphan transporters. They are classified into two large superfamilies, the solute carrier (SLC) family and the ATP-binding cas- Fig. 1 . Transporters acting in the hepatobiliary and tubular secretion of drugs in human BSEP: bile salt export pump, MATE: multidrug and toxin extrusion protein, MRP: multidrug resistance associated protein, BCRP: breast cancer resistant protein, P-gp: P-glycoprotein, NTCP: sodium-taurocholate cotransporting polypeptide, OCT: organic cation transporter, OATP: organic anion transporting polypeptide, OAT: organic anion transporter, PEPT: peptide transporter, BA -: bile acids, OA -: organic anion, OC ＋ : organic cation sette (ABC) protein family. The SLC family contains 364 proteins classified into 48 subfamilies, whereas the ABC protein family contains 49 proteins classified into seven subfamilies. The SLC-type transporters mediate facilitated diffusion (so-called``downhill transport'') and secondary active transport (so-called``uphill transport''), coupled to the symport or antiport of ions or lowmolecular-weight compounds to provide the driving force. ABC transporters have conserved catalytic domains for ATP hydrolysis (ATP binding cassette) and mediate the primary active transport in unidirectional efflux. Among the transporters, those involved in the drug disposition are referred to as drug transporters. Drug transporters are characterized by their broad substrate specificities, and accept diverse structurally unrelated compounds as substrates. Determining the molecular identities of drug transporters has allowed the identification of their specific inhibitors and substrates, and the disruption of transporter genes in mice. These experimental tools facilitate the evaluation of the contributions of transporters to tissue uptake and efflux processes in vitro and in vivo. The importance of drug transporters in drug disposition in humans has been suggested by in vitro transport studies using human materials such as cryopreserved hepatocytes, kidney slices, and membrane vesicles, and clinically relevant drug-drug interactions involving the inhibition of drug transporters. 1, 4, 5) Mutations and polymorphisms in transporter genes have also been found, which cause interindividual and ethnic differences in transporter functions and expression, leading to differences in drug dispositions and responses. Clinical studies that have focused on such polymorphisms also support the importance of drug transporters in drug disposition in humans. Currently, important transporters involved in drug disposition include OATP/SLCO, OAT/SLC22, OCT/SLC22, P-glycoprotein/MDR1, MRP2/ABCC2, MRP3/ ABCC3, MRP4/ABCC4, and BCRP/ABCG2 (Fig. 1 , Table  1 ). This article reviews our current knowledge of the significant roles played by drug transporters in drug disposition and responses, focusing particularly on the transporters expressed in the clearance organs (liver and kidney), and at the blood-brain barrier, and on the in vitro-in vivo extrapolation (IVIVE) used to predict drug disposition in vivo.
Role of transporters in the systemic elimination of drugs Rate-limiting step in transporter-mediated tissue elimination: The extraction of drugs during a single pass through an organ is determined by the blood-flow rate, protein binding in the blood and the ability of the organ to remove drugs from the blood circulation. Intrinsic organ clearance (CLint, org) is the kinetic parameter representing the ability of the organ for drug metabolisms and excretion into the bile or urine. When drugs can permeate the membrane sufficiently quickly to achieve a rapid equilibrium and equal unbound concentration between the capillary and intracellular spaces, CLint, org equals the intrinsic organ clearance based on the unbound concentration in the tissue (CLint) (Eq. 1):
CLint, org ＝CL int Eq. 1
However, most anionic drugs, and some hydrophilic organic cations and zwitterions exhibit poor membrane Under these conditions, the hepatic uptake becomes the rate-limiting process in the overall hepatic elimination, so-called``uptake limited''. Neither CLint nor PSeff makes any contribution to the systemic exposure to the drug. On the contrary, when PSeff is greater than CLint, CLint and PSeff are proportional and inversely proportional to CLint, org, respectively (Eq. 4).
CLint, org ＝PS inf ･CL int/PSeff Eq. 4
Therefore, unlike the uptake process, considering the rate-limiting process is important when predicting the effects of fluctuations in metabolism and canalicular efflux resulting from drug-drug interactions or genetic polymorphisms. For instance, CLint for metabolic clearance has been successfully predicted in vitro using human liver microsomes. Equation 2 suggests the possible over-or underestimation of in vivo clearance even though the metabolism is the predominant elimination pathway if the concentration of the unbound drug in the cells is not considered. Obach reported that the anionic drugs, such as ibuprofen, tend to exhibit poor prediction of in vivo CLint from in vitro using human liver microsomes.
6)
The poor prediction may be accounted for by the involvement of uptake transporter in the hepatic elimination of the acidic drugs. In addition, it has been demonstrated that transporters play major roles in the hepatic uptake of some drugs whose major elimination pathway is metabolism (see``Role of active efflux transporters at the blood-brain barrier'').
A comparison of intrinsic uptake clearance (determined by integration plot analysis, the multiple indicator dilution method, or liver perfusion) and intrinsic organ clearance provide clues to the rate-limiting process (Eq. 3, 4). When the uptake clearance is almost equal to the hepatic intrinsic clearance, the uptake process is the ratelimiting process in the overall elimination. Only a few studies have examined the rate-limiting process in hepatic elimination. Uptake is rate limiting for the hepatic elimination of pravastatin and methotrexate in rats, 7, 8) and is suggested to be rate limiting for the hepatic elimination of pravastatin in humans. 7) It must be noted that the rate-limiting process in hepatic elimination of methotrexate is species dependent. The hepatic elimination of methotrexate is uptake limited in rats but not in mice, because of species differences in the transport activities in both sinusoidal and canalicular efflux. 8, 9) Differences in sensitivity to the inhibition of CYP3A4 with systemic exposure to statins suggest that the hepatic elimination of atorvastatin is also uptake limited. Concomitant treatment with itraconazole greatly increases the AUC of the plasma concentrations of simvastatin and lovastatin, by more than 10-fold, whereas the effect on the AUC of the plasma concentrations of atorvastatin is less marked, at 3-fold although metabolism by CYP3A4 is the major elimination pathway for atorvastatin as in the case of simvastatin and lovastatin. 10) The difference in the sensitivity to itraconazole may be ascribed to a difference in the rate-limiting step, i.e., the hepatic elimination of atrovastatin is uptake limited, but not for simvastatin and lovastatin because the hepatic uptake of atorvastatin is mediated by OATP1B1, whereas simvastatin and lovastatin are given by the lactone form with sufficient membrane permeability by passive diffusion. 10) The relationship between transport activities and the AUC of the liver concentration (AUCh) is discussed in this section. When drugs are given intravenously, AUCh is expressed by the following equation 7) : Dose fh･AUCh
where fh and fb represent the unbound fractions in the liver and blood, respectively, Qh represents the hepatic blood-flow rate, and CLr represents the renal clearance. When renal clearance is negligible (CLr¿0), Eq. 5 can be simplified to Eq. 6.
AUCh＝Dose/fh･CLint Eq. 6
Equation 5 and 6 suggest that liver exposure (AUCh) depends only on the intrinsic clearance for sequestration, irrespective of the rate-limiting process, and that, when hepatic elimination is the sole source of elimination, AUCh is not influenced by changes in uptake clearance (PSinf) or efflux clearance (PSeff). For example, decreased uptake clearance will increase plasma concentrations. 
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IVIVE of Membrane Transport
These two opposing changes have no net effect on liver exposure.
7)
IVIVE of hepatic elimination: The IVIVE of hepatic metabolism using human liver microsomes successfully predicts the in vivo hepatic metabolic clearance of drugs.
11)
IVIVE is also helpful in predicting the in vivo parameters of hepatic uptake, sinusoidal efflux, and canalicular efflux. In vitro and in vivo methods for evaluating hepatic elimination was summarized in Figure 2 . Watanabe et al. challenged the IVIVE of the hepatobiliary transport of pravastatin, and this section introduces our IVIVE method.
7)
A scaling factor is introduced to extrapolate in vitro parameters to in vivo ones, in addition to physiological scaling factors, such as cell number per unit tissue weight and tissue weight per unit body weight. Assuming that there are no large interspecies differences between rats and humans, the scaling factor determined in rats is used to extrapolate human in vitro parameters to those of in vivo.
For hepatic uptake, freshly isolated rat hepatocytes and cryopreserved human hepatocytes were used to determine PSinf in vitro. The uptake of drugs increases linearly during cellular uptake, the so-called``initial uptake'', to give the in vitro PSinf. The PSinf of five compounds, determined in vitro using freshly isolated rat hepatocytes, gave a 1:1 relationship with the uptake clearance determined in situ using the multiple indicator dilution method. However, in situ PSinf appeared not to increase linearly when in vitro PSinf was greater than 10 ml/min/g liver presumably because the diffusion across the unstirred water layer becomes rate-limiting process.
12)
Watanabe et al. determined the hepatic uptake of pravastatin using freshly isolated rat hepatocytes, and compared in vitro PSinf corrected with the physiological scaling factor with in vivo hepatic intrinsic clearance calculated using the dispersion model to determine the scaling factor of 3.5 for hepatic uptake. Multiplying this scaling factor with the in vitro PSinf determined with cryopreserved human hepatocytes gives an in vivo PSinf close to the in vivo hepatic intrinsic clearance, suggesting that the uptake process is also a rate-limiting process in humans.
For the IVIVE of the canalicular efflux of pravastatin, canalicular membrane vesicles were used, which exhibit the ATP-dependent accumulation of organic anions inside them. Membrane vesicles have two orientations; i.e., physiological orientation (right side out) and inverted orientation (inside out). Only in inside-out-oriented membrane vesicles are the ATP binding cassettes (the cytoplasmic domains of ABC transporters) exposed to buffer, allowing the free access of ATP to the domain. Therefore, for IVIVE, the fraction of inside-out-oriented membrane vesicles (IO) must be taken into consideration:
Eq. 7
where vinitial represents the initial uptake velocity, R represents the recovery, and E represents the enrichment. An in vivo study of Eisai hyperbilirubinemic rats (EHBR) hereditarily lacking Mrp2 demonstrated that the saturable fraction of biliary excretion was reduced in Fig. 3 . Physiologically-based pharmacokinetic models, and the simulated plasma concentration time profiles of pravastatin following intravenous and oral administration (A) The liver consists of five compartment connected serially to mimic the dispersion model, (B) The plasma concentrations were simulated using the PBPK model and kinetic parameters extrapolated from in vitro using scaling factors determined in rats. Open and closed circles represent the observed values, and rigid lines represent the simulated values. Cited from.
7)
EHBR.
13)
The ATP-dependent uptake of pravastatin by human canalicular membrane vesicles was determined, to obtain CLCMV in humans, and was extrapolated to an in vivo parameter by multiplying it by the scaling factor determined in rats. Considering the in vivo biliary clearance in terms of the hepatic concentrations and CLCMV gave a scaling factor of 21. In addition to canalicular membrane vesicles, sandwich-cultured hepatocytes (SCH) are another in vitro research tool with which to determine biliary clearance. SCH form bile canaliculi, which are disrupted by incubating the cells without Ca
2＋
. Therefore, the comparison of the uptake of a test drug with and without Ca 2＋ indicates the amount of drug excreted into the bile canaliculi.
14)
The biliary excretion indices of anionic drugs, defined as the ratio of the amount excreted into the bile canaliculi to the total amount of drug associated with the cells and bile canaliculi, correlated well with their in vivo biliary clearances based on the plasma concentrations, although there were large gaps in the absolute values. 15, 16) SCH can be an in vitro model for evaluating the hepatobiliary transport of drugs although whether the canalicular efflux clearance is preserved remains unknown. Unlike uptake and canalicular efflux, currently, no in vitro method to determine sinusoidal efflux clearance directly has been established, and it is therefore assumed to be equal to passive diffusion.
The IVIVE of the hepatobiliary transport of pravastatin successfully predicted the plasma concentration-time profiles of pravastatin following its intravenous and oral administration in humans (Fig. 3) . However, it should be noted that since the hepatic elimination of pravastatin was predicted to be uptake limited in humans, whether the intrinsic biliary clearance based on the liver concentration is successfully predicted or not remains unknown. The hepatic intrinsic clearance determined in clinical studies is a hybrid parameter, as shown in Eq. 2, and the parameters of each membrane transport process cannot be separately determined, so the predicted parameters cannot be validated. This must be overcome in the future.
IVIVE of renal elimination: The kidney is composed of nephrons consisting of different segments, from the glomeruli to the distal tubules. The renal elimination of drugs is determined by glomerular filtration, tubular secretion, and reabsorption:
where CLr represents the renal clearance, GFR represents the glomerular filtration rate, CLsec represents the clearance for tubular secretions, and Fr represents the fraction of reabsorption. Glomerular filtration is sizeselective filtration, so only unbound drugs in the plasma undergo glomerular filtration (first term on the right side of Eq. 8). Tubular secretion occurs in the proximal tubules formed by epithelial cells, which are polarized cells with basolateral and brush-border membranes. Transporters play significant roles in the uptake and subsequent efflux into the lumen on the basolateral and brushborder membranes, respectively, allowing efficient directional transport across the proximal tubules. The renal elimination of drugs in humans has been predicted with empirical interspecies scaling based on al-lometry. 17, 18) In this prediction method, it is assumed that species differences in the renal clearance are ascribable to differences in the numbers of nephrons, the minimum unit of the kidney, and not to differences in the tubular secretion activity per nephron. The disadvantage of the empirical method is that it cannot rule out exceptional cases. For instance, there is a large difference between the predicted and observed values for the renal clearance of enprofylline, but of which mechanism is an unknown. 19) IVIVE based on the molecular mechanism has not yet been established because the in vitro methods that examine tubular secretion are still limited.
As one of in vitro systems, kidney slices have been used, including those prepared from nephrectomized human kidney. [20] [21] [22] [23] Because kidney slices consist of multiple layers of epithelial cells, the uptake clearance determined in kidney slices underestimates the in vivo tubular secretion clearance. 23) Furthermore, the uptake by slices prepared from rat kidney appears to reach a plateau for OAT1 and OAT3 substrates, such as estrone sulfate, dehydroepiandrosterone sulfate, and 2,4-dichlorophenoxyacetate, presumably by diffusion-limited uptake. 23) Despite such disadvantages, the uptake of drugs by kidney slices can give a linear regression curve with in vivo clearance for the tubular secretion of drugs with moderate to low renal clearance. IVIVE using human kidney slices must be challenged in the future. An ideal system for the evaluation of efflux processes and reabsorption with IVIVE has not been established. Brush-border membrane vesicles (BBMVs) from the kidney have been used to investigate the transport mechanisms of drugs in the kidney. The efflux mechanisms for anionic drugs in the kidney involve transporters with different driving forces (see``Organic cation transport system''). BBM vesicles prepared from the kidney are predominantly right-sideout oriented, 24, 25) and they cannot be used for the detection of the transport activities of ABC transporters, although some of them have been shown in vivo to mediate luminal efflux in the kidney (see``Role of transporters in other peripheral organs'').
Transporters in hepatic elimination: Hepatocytes are polarized cells and express different transporters in the blood-facing sinusoidal and canalicular membranes (Fig. 1) . Transporters in the sinusoidal membrane mediate uptake from the systemic circulation. In particular, the substrates of OATP1B1/SLCO1B1 include clinically important drugs, such as HMG-CoA reductase inhibitors (statins), angiotensin II receptor antagonists, and angiotensin-converting enzyme inhibitors.
1)
Hepatocytes also express an OATP1B1 homologue, OATP1B3/ SLCO1B3, which is more abundant in the hepatocytes around the central vein than in those around the portal vein. 26) Because of their overlapping substrate specificities, the contributions of OATP1B1 and OATP1B3 are critical factors in predicting the significance of inhibition and genetic polymorphisms in the systemic exposure to substrate drugs. Hirano et al. proposed two methods using cryopreserved hepatocytes to estimate relative contribution of OATP1B1 and OATP1B3: (i) inhibition using a selective inhibitor (estrone sulfate as the OATP1B1 inhibitor), and (ii) scaling up the uptake by OATP1B1-HEK and OATP1B3-HEK cells using the relative activity factor. 27 )``R elative activity'' is defined as the ratio of the uptake of reference compound or protein expression determined in cryopreserved human hepatocytes to that in OATP1B1-HEK and OATP1B3-HEK cells. Using these methods, in vitro uptake studies using cryopreserved human hepatocytes have suggested that OATP1B1 plays a major role in the uptake of pravastatin, pitavastatin, rosuvastatin, and estradiol-17b-glucuronide, whereas the hepatic uptake of fexofenadine, valsartan, olmesartan, and bosentan is mediated by OATP1B1 and OATP1B3, with similar contributions.
Most of the hepatic uptake of telmisartan and its glucuronide is mediated by OATP1B3.
28)
The OATP1B1 substrates include drugs whose main sequestration pathway is metabolism in the liver. These include CYP3A4 substrates such as simvastatin and atorvastatin, CYP2C8 substrates such as repaglinide and cerivastatin, and the CYP3A4 and CYP2C9 substrate nateglinide. [29] [30] [31] [32] [33] As discussed previously, these transporters are the predominant factors of systemic exposure to their substrate drugs (Fig. 4) . Uptake transporters plays an indispensable role in maximizing the liver exposure to statins, in particular, because their pharmacological target is HMG-CoA reductase, a cytosolic enzyme in the liver, but the systemic exposure of the peripheral organ, such as muscle, to statins is minimized to avoid their adverse reactions, myopathy and rhabdomyolysis. Indeed, systemic exposure to OATP1B1 substrates is affected by drugdrug interaction and genetic polymorphisms/mutations of OATP1B1. The concomitant use of cyclosporin A significantly increased the systemic exposure to cerivastatin in patients undergoing kidney transplantation. Shitara et al. demonstrated that this drug-drug interaction includes the inhibition of the hepatic uptake mediated by OATP1B1. 33) Rimpicin is also a clinically relevant inhibitor of OATP1B1, and it greatly increased the systemic exposure to atorvastatin in healthy volunteers by inhibiting its hepatic uptake. 34) To date, 20 single-nucleotide polymorphisms (SNPs) of OATP1B1 have been reported, which form 15 haplotypes. 1) Of these haplotypes, OATP1B1 * 5 (V174A) and OATP1B1 * 15 (N130D, V174A) exhibit reduced transport activities compared with the reference haplotype OATP1B1 (OATP1B1*1a), resulting in a significant increase in the systemic exposure to anionic drugs, such as repaglinide, simvastatin, and atorvastatin, as well as to valsartan, temocapril, pravastatin, and pitavastatin, in subjects with these haplotypes. [29] [30] [31] [32] [35] [36] [37] Recently, it was shown that a SNP of 
. Effect of functional changes of PS inf (A) and CL int, bile (B) on the plasma and liver concentrations of pravastatin
Plasma and liver concentrations after oral administration in human were simulated using the PBPK model with varying hepatic uptake or efflux transport activities over a 1/3-3-fold range of the initial values. (-; initial, ---; ×1/3, -----; ×3). Cited from.
7)
OATP1B1, which is in nearly complete linkage disequilibrium with a nonsynonymous SNP (V174A), is associated with the risk of myopathy caused by simavastatin medication (odds ratio 17 in CC homozygotes compared with TT homozygotes), presumably because of the greater systemic exposure to simvastatin due to lower hepatic uptake caused by the nonsynonymous SNP (V174A) of OATP1B1. 38) Theoretically, as discussed in``IVIVE of hepatic elimination'', when renal elimination is negligible, the exposure of drugs in the liver depends only on the sequestration clearance and is independent of the uptake activity. When drugs undergo significant renal elimination, as does pravastatin, the increase in the AUC of the plasma concentration is not high enough to compensate for the reduced hepatic uptake activity (Fig. 4) . Therefore, hepatic exposure to such drugs will be reduced, resulting in a weaker pharmacological effect. The cholesterollowering effect of pravastatin is slightly weaker for a short time in subjects with the OATP1B1*5 or OATP1B1*15 haplotype, 39, 40) although the chronic effect is similar, irrespective of the OATP1B1 genotype. 40, 41) This is reasonable because pravastatin undergoes renal elimination. 10) Simulations have shown that the liver concentration of pravastatin is slightly reduced when the hepatic uptake clearance is reduced (Fig. 4) .
Renal elimination makes a negligible contribution to the pharmacokinetics of other statins, such as simvastatin, lovastatin, and atorvastatin, so hepatic uptake will not cause interindividual differences in the pharmacological response. Equation 7 suggests that, rather than the uptake process, changes in metabolic clearance and/or biliary clearance greatly affect the pharmacological action of statins. However, this has not yet been examined.
The cooperative role of the uptake transporters OATP1B1 and OATP1B3, and canalicular efflux transporters, such as P-glycoprotein/MDR1, MRP2/ABCC2, and BCRP/ABCG2, has been demonstrated in the efficient hepatobiliary transport of drugs. 1, 42, 43) Indeed, the lack of MRP2 impairs the biliary excretion of anionic drugs in rats, 44) and the lack of Bcrp reduced the biliary excretion of pitavastatin and some fluoroquinolones. 45, 46) Furthermore, the simultaneous expression of hepatic uptake transporters (OATP1B1 or OATP1B3) and canalicular efflux transporters (P-gp, MRP2, and BCRP) in MDCK II cells, where uptake and efflux transporters are expressed on the basal and apical membranes, respectively, reconstitutes the efficient directional transcellular transport of their common substrates in a basal-to-apical direction. [47] [48] [49] [50] Intriguingly, double transfectants have shown overlapping substrate specificities for human canalicular efflux transporters, 46, 49) indicating the need for a method to determine the key transporter. In addition to ABC transporters, MATE1, an SLC-type transporter mediating the exchange of organic cations and H ＋ , has been identified on the canalicular membranes of hepatocytes 51) although its significance in the canalicular efflux of its substrate drugs has not been examined. Subjects with OCT1 variants exhibited greater areas under the plasma concentration curves for metformin, suggesting that metformin undergoes hepatic elimination. 52) MATE1 may mediate the biliary excretion of metformin via the canalicular membrane.
In addition to their uptake and canalicular efflux, transporters mediating the sinusoidal efflux have recently been found in mice. MRP3 and MRP4 are the members of the ABCC family and are expressed on the sinusoidal membrane of hepatocytes. Considering the transport direction of MRP3-and MRP4-mediated transport (efflux into the blood circulation from the liver), their transport activities are associated with PSeff in Eq. 2. Therefore, as discussed in the section``Rate-limiting step in transporter-mediated tissue elimination'', MRP3 and MRP4 make only a negligible contribution to the hepatic elimination of drugs whose hepatic elimination is uptake limited, or to the liver concentrations of its substrate drugs even though the drugs are efficiently transported by MRP3 and MRP4. Mrp3 -/-mice exhibited less systemic exposure to morphine-6-glucuronide and methotrexate than did the wild-type mice. 9, 53) The hepatic uptake clearance of methotrexate is blood-flow limited, but its hepatic clearance is not, indicating that methotrexate undergoes significant sinusoidal efflux in the mouse liver. Therefore, reduced sinusoidal efflux increases the hepatic clearance of methotrexate. 9) As for Mrp4, there is only limited information. It mediates the sinusoidal efflux of sulfate conjugates in the liver, 54) but makes a limited contribution to that of glucuronide conjugate, fexofenadine and methotrexate. 9, 54, 55) Transporters in the renal elimination of anionic drugs:
Organic anion transport system The organic anion transport system in the kidney comprises two multispecific organic anion transporters, OAT1/SLC22A6 and OAT3/SLC22A8 (Fig. 1) . 3, 43) In addition to OAT1 and OAT3, the basolateral membranes of the proximal tubules express OAT2/SLC22A7 56) and OATP4C1/SLCO4C1 57) in the human kidney, although their functional significance is unknown. To concentrate anionic drugs in the epithelial cells, both OAT1 and OAT3 mediate active transport. 3, 43) p-Aminohippurate and benzylpenicillin are relatively specific inhibitors of OAT1 and OAT3, and a comparison of their inhibition potencies suggests that OAT1 and OAT3 contribute to the renal uptake of organic anions. 20) An in vitro uptake study using kidney slices evaluated the contribution of OAT1 and OAT3 to the renal uptake of organic anions.
Their substrate specificities overlap, but OAT1 makes a greater contribution to the renal uptake of lowmolecular-weight organic anions, such as p-aminohippurate and antiviral drugs (adefovir, cidofovir, and tenofovir), whereas OAT3 makes a greater contribution to the renal uptake of bulky amphipathic organic anions, such as statins, sartans, and benzylpenicillin, which are substrates of hepatic organic anion transporters. [20] [21] [22] [23] Furthermore, OAT3 accepts some cationic drugs, such as H2 receptor antagonists, and zwitterions such as fexofenadine. 58, 59) The roles of OAT1 and OAT3 in the kidney were clearly demonstrated in an in vivo/in vitro study using Oat1
-/-and Oat3 -/-mice. The Oat1 -/-mice exhibited delayed elimination of p-aminohippurate and diuretics (furosemide and bendroflumethiazide), 60, 61) and the Oat3 -/-mice exhibited delayed elimination of benzylpenicillin, methotrexate, diuretics (furosemide and bendroflumethiazide), and ciprofloxacin (only in female mice). [61] [62] [63] [64] The pharmacological target of some diuretics is located in the lumen. The lack of OAT1 and OAT3 reduces the effective concentration of the drug in the lumen and thereby attenuates the diuretic effect of furosemide and bendroflumethiazide in mice. 60, 61) The transporters mediating the luminal efflux have not been fully identified. Classically, transport studies using BBMV have suggested that the luminal transport of organic anions consists of two distinct systems: (i) the electroneutral exchange of organic anions and (ii) voltagedriven facilitated transport. There are several candidate transporters, including NPT1 and mUrat1, 65, 66) although their in vivo significance remains to be investigated. In addition, to these transport systems, ABC transporters mediating primary active transport, such as breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance associated proteins 2 (MRP2/ABCC2) and 4 (MRP4/ABCC4), have been shown to constitute a third efflux mechanism in the kidney (Fig. 1) . [67] [68] [69] Knockout mice have been generated for these transporters, which allow the analysis of the importance of these transporters. According to Eq. 2 and Eq. 6, unless the transporter accounts for the major part of the luminal efflux, the lack of that transporter will not affect tubular clearance with regard to the plasma concentrations, but it will instead significantly increase the kidney concentration. Indeed, the lack of Mrp4 caused a significant increase in the kidney concentrations of trichlorothiazide, cephalosporins (ceftizoxime and cefazolin), and antiviral drugs (adefovir and tenofovir) when they were given intravenously by constant infusion, indicating that Mrp4 makes a significant contribution to the luminal efflux of these drugs in the kidney. [70] [71] [72] Because the tubular secretion of these drugs remains intact even in Mrp4 -/-mice, other transporters are also involved in luminal efflux. In addition to MRP4, subjects with a SNP or mutation in MRP2 exhibited delayed elimination of methotrexate via systemic mice represents the contribution of Bcrp to the net efflux at the BBB. The transcellular transports of Bcrp substrates were determined across the monolayers of mock, and Bcrp-MDCK II, and Mdr1a-LLC were determined in the basal-to-apical and apical-tobasal orientation. CFR, the ratio of the basal-to-apical to the apicalto-basal transport across monolayers of epithelial cells expressing Bcrp or P-gp divided by the corresponding ratio in mock cells, represents the Bcrp-or P-gp-mediated efflux activity relative to passive diffusion Data were cited from reference 90) elimination, suggesting the involvement of MRP2 in the luminal efflux. 73, 74) Organic cation transport system OCT2/SLC22A2 is the predominant organic cation transporter in the basolateral membrane of the proximal tubules. 75) OCT2 mediates the facilitated diffusion of various cationic drugs, including metformin and cimetidine. 75) The luminal efflux mechanism for hydrophilic organic cations is suggested to be active because the outward concentration gradient of H ＋ enhances the uptake of typical cationic compounds into brush-border membrane vesicles. 76) Initially, OCTN1/SLC22A4 and OCTN2/ SLC22A5 were considered candidates because in an expression system, they mediated the antiport of tetraethylammonium, a typical substrate of renal organic cation transporters with H ＋ . 77, 78) More recently, MATE proteins have also been identified, comprising Mate1 in the rodent kidney and MATE1/SLC47A1 and MATE2K/ SLC47A2 in the human kidney. 51, 79) The MATE proteins accept organic cations, which are excreted into the urine without metabolism. 80) MATE proteins are now considered to be responsible for the antiport of organic cations with protons in the kidney.
Role of transporters in the peripheral organs
In addition to their action in systemic elimination, transporters act as factors that determine drug exposure in the peripheral organs. This is most evident in tissues with blood-tissue barriers between the parenchymal compartment and the blood, such the brain, testis, and retina. At these barriers, transporters actively extrude drugs into the blood, thereby limiting the tissue penetration of the drugs (Fig. 5) . When drugs undergo active efflux at the blood-tissue barrier, the unbound concentration in the extracellular fluid in the parenchyma is lower than that in the plasma. Therefore, even though the systemic exposure is similar, their exposure in the tissue is lower. Because the pharmacological actions/adverse reactions of drugs depend on their concentrations in the parenchymal compartment, the transporters at blood-tissue barriers can attenuate the effects of drugs in the tissue compartment. In this section, the role of transporters at the blood-brain barrier is discussed.
Role of active efflux transporters at the bloodbrain barrier: Transporters actively extrude drugs into the circulating blood at the blood-brain barrier, thereby limiting their tissue penetration from the circulating blood. Because of this active efflux, the drug concentration in the brain interstitial space is lower than the unbound concentration in the plasma. Producing mice lacking P-gp (Mdr1a, or Mdr1a and Mdr1b) has allowed the investigation of its significance in limiting the penetration of drugs to the brain. A number of drugs ex- Fig. 7 . Synergetic effect of P-gp and BCRP impairment on the brain-to-plasma concentration ratio of the common substrates K p, brain ratio (P-gp), K p, brain ratio (BCRP) and K p, brain ratio (DKO) represent the ratio of K p, brain in wild-type and P-gp -/-, wild-type and BCRP -/-, and wild-type and P-gp -/-/BCRP -/-mice, respectively.
hibit greater brain concentrations in Mdr1a -/-and Mdr1a/1b -/-mice compared with those in wild-type mice, 81, 82) resulting in enhanced sensitivity to the neurotoxic effects of ivermectin and the effects of asimadoline on the central nervous system. 83, 84) To predict quantitatively the effect of P-gp on the brain concentrations of test compounds, Adachi et al. (2001) and Yamazaki et al. (2001) proposed a prediction method based on an in vitro assay. 85, 86) They showed that the corrected flux ratio (CFR), the ratio of the basal-to-apical to the apical-tobasal transport across monolayers of epithelial cells expressing P-gp divided by the corresponding ratio in mock cells, represents the P-gp-mediated efflux activity relative to passive diffusion. Therefore, a CFR greater than one indicates that the transporter is quantitatively significant in the net transport. The ratio of the brain-to-plasma concentration ratio in wild-type mice to that in Mdr1a -/-or Mdr1a/1b -/-mice gives a quantity similar to CFR;, i.e., the in vivo P-gp-mediated efflux activity relative to passive diffusion. Therefore, the CFR and the ratio of brainto-plasma concentration ratio should show a linear correlation. Indeed, the plot of CFR against the ratio of the ratio does show a linear relationship.
Bcrp -/-and Mrp4 -/-mice have also been produced. 87, 88) Bcrp -/-mice exhibit greater brain concentrations of phytoestrogens such as daidzein, genistein, and coumestrol, food-derived carcinogens such as PhIP, Nhydroxyl PhIP, and MeIQx, and drugs such as dantrolene and prazosin, 89, 90) and Mrp4
-/-mice exhibit delayed elimination of topteocan, adefovir, and the acid form of oseltamivir (Ro64-0802) from the brain. 88, 91, 92) It should be noted that the CFR of the BCRP substrates showed no positive correlation with the increase in the ratio of the brain-to-plasma concentration ratio of wild-type mice to that of Bcrp -/-mice (Fig. 6) . Because some Bcrp substrates are P-gp substrates, 89) P-gp may be involved in the efflux of these Bcrp substrates together with Bcrp, attenuating the effect of Bcrp impairment on the brain drug concentrations. Recently, knockout mice lacking both P-gp and Bcrp (P-gp -/-/Bcrp -/-mice) exhibited a marked increase in the brain concentration of erlotinib compared with those of knockout mice lacking P-gp or Tc-mebrofenin 101) metabolite of cysteinyl leukotriene:
11
C N-acetyl-leukotriene E4 102) MRI contrast agent: B22956/1 113) Multidrug resistance associated protein 3 (MRP3/) hepatobiliary scintigraphy agent: 99m Tc-mebrofenin 101) Bcrp.
93)
The increase in the Kp, brain of the common substrates in the P-gp -/-/Bcrp -/-mice looks synergism of the efflux transporters at the BBB. Figure 7 illustrates the kinetic concept of this apparent synergism. When both P-gp-and Bcrp-mediated transport are significantly greater than the passive diffusion, P-gp-or Bcrp-mediated efflux remained in the single knockout mice prevents a marked reduction in the luminal efflux clearance (PSluminal). This is why such synergism in the Kp, brain can be observed in the double knockout mice. Therefore, that a moderate increase in Kp, brain of the common substrates in the single knockout mice indicates low contribution of the transporter to the net luminal efflux. However, it acts as a safety system against the brain penetration of the common substrates when other efflux transporter is dysfunctional.
Positron emission tomography has been used to investigate the efflux transport across the human blood-brain barrier, which allows the real-time measurement of the total radioactivity in the human brain. Some P-gp substrates have been used as probes for positron emission tomography. 94) In rhesus monkeys, pretreatment with PSC833, a potent P-gp inhibitor, caused a significant increase in the permeation of 11 C-verapamil, determined by integration plot analysis.
95)
The ratio of the AUC for 11 Cverapamil in the brain and plasma, representing the brain-to-plasma concentration ratio, was 1.9-fold greater in subjects treated with cyclosporin A than that in control subjects, presumably reflecting the inhibition of active efflux at the blood-brain barrier, 96) although the inhibition of P-gp at the blood-brain barrier by cyclosporin A was not clinically relevant, despite the extraordinarily high dose of cyclosporin A given.
Role of transporters in other peripheral organs: The biguanide metformin, an inhibitor of mitochondrial respiration complex I, is an antidiabetic drug. The major elimination pathway of metformin is the kidney, whereas the pharmacological target organ is the liver, where it inhibits gluconeogenesis. Because of the drug's hydrophilicity, transporters play a predominant role in both its hepatic distribution and its renal elimination. OCT1 plays a particularly essential role in the hepatic uptake of metformin, and a lack of OCT1, a hepatic organic cation transporter, diminishes its hepatic distribution, 97) thereby attenuating the inhibition of gluconeogenesis and its adverse reaction, lactic acidosis. 98) This has also been observed clinically. SNPs causing the loss of the transport activity of OCT1 are associated with weaker pharmacological effects of metformin. 52) The significance of MRP4 in other peripheral organs has been suggested. The toxicity of adefovir and 6-thioguanine is greatly enhanced in peripheral organs, such as the bone marrow, spleen, thymus, gastrointestinal tract, and myelopoietic cells, whereas the systemic exposure is similar in wild-type and Mrp4 -/-mice.
99)
Conclusion
As summarized in this review article, animal and clinical studies have provided an enormous amount of data showing the importance of transporters in drug disposition. Although the human materials for in vitro transport studies have been available for characterization of tissue uptake and efflux of drugs, the IVIVE for the membrane transport of drugs remains premature. This is primarily due to the lack of the corresponding in vivo kinetic parameters for determining scaling factors to extrapolate of in vitro parameter to in vivo, and thus, the predictability and reliability remained in question. To overcome this problem, tissue concentrations must be determined in addition to blood concentration. Therefore, clinical studies using imaging technologies, such as single-photon emission computed tomography (SPECT), positron emission tomography (PET) and magnetic resonance imaging (MRI) will contribute to increase the predictability/reliability in IVIVE of membrane transport of drugs. The disadvantage of these imaging technologies is that they require radioactive tracer material for SPECT and PET introduced isotope such as (Table 2) . Gadoxetate, a magnetic resonance imaging contrast agent, is a substrate of the hepatic organic anion transporter, OATP1A1.
100) 99m
Tc-mebrofenin, which undergoes hepatobiliary transport, is a substrate of OATP1B1, OATP1B3, MRP2, and MRP3. 101) The elimination of N-[ 11 C]acetyl-leukotriene E4 from the liver was markedly delayed in mutant rats hereditarily lacking Mrp2. 102) These reagents will allow the quantification of hepatic uptake and biliary excretion separately in humans, providing parameters for the validation of predicted parameters. The probes for specific transporters will also be powerful tools with which to investigate the significance of target transporters in drug disposition, drug-drug interaction mechanisms, and the effects of genetic polymorphisms/mutations. Together with probes, specific inhibitors that can be administered clinically must also be established in the future. Further studies are necessary, particularly to establish these probe substrates and inhibitors for clinical studies.
